Abstract
Aortitis can be the manifestation of an underlying infectious or noninfectious disease process. An autoimmune cause is suggested in a large proportion of noninfectious causes. Similar to other autoimmune diseases, the pathophysiology of aortitis has been investigated in detail, but the etiology remains unknown. Most cases of aortitis often go undetected for a long time and are often identified at late stages of the disease. Recent advances in imaging techniques have significantly improved the diagnosis of aortitis. However, significant challenges associated with the imaging techniques limit their use. Several routine inflammation-based markers, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and inflammatory cytokines, are nonspecific and, therefore, have limited use in the diagnosis of aortitis. The search for more specific serum biomarkers, which can facilitate detection and progression is under progress. Several autoantibodies have been identified, but assigning their role in the pathogenesis as well as their specificity remains a challenge. The current review addresses some of these issues in detail.
Key messages
• Noninfectious aortitis is an autoimmune disease.
• Several biomarkers, including cytokines and autoantibodies, are increased in aortitis.
• Imaging techniques, commonly used to detect aortitis, are associated with the high cost and technical challenges.
• There is a need to develop low-cost biomarker-based detection tools.
• The knowledge of biomarkers in aortitis detection is discussed.
Similar content being viewed by others
References
Bossone E, Pluchinotta FR, Andreas M, Blanc P, Citro R, Limongelli G, Della Corte A, Parikh A, Frigiola A, Lerakis S, Ehrlich M, Aboyans V (2016) Aortitis. Vasc Pharmacol 80:1–10
Gornik HL, Creager MA (2008) Aortitis. Circulation 117(23):3039–3051
Ramirez FD, Jamison BM, Hibbert B (2016) Infectious aortitis. Int Heart J 57(5):645–648
Caspary L (2016) Inflammatory diseases of the aorta. VASA Zeitschrift fur Gefasskrankheiten 45(1):17–29
Skeik N, Ostertag-Hill CA, Garberich RF, Alden PB, Alexander JQ, Cragg AH, Manunga JM, Stephenson EJ, Titus JM, Sullivan TM (2017) Diagnosis, management, and outcome of aortitis at a single center. Vasc Endovasc Surg 51(7):470–479
Nwadibia U, Larson E, Fanciullo J (2016) Polymyalgia rheumatica and giant cell arteritis: a review article. S D Med 69(3):121–123
Chen JJ, Leavitt JA, Fang C, Crowson CS, Matteson EL, Warrington KJ (2016) Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology 123(9):1999–2003
Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2009) Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 88(4):221–226
Geiger J, Ness T, Uhl M, Lagreze WA, Vaith P, Langer M, Bley TA (2009) Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology (Oxford) 48(5):537–541
Johnston SL, Lock RJ, Gompels MM (2002) Takayasu arteritis: a review. J Clin Pathol 55(7):481–486
Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C (2017) Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 13(8):476–484
Sreih AG, Alibaz-Oner F, Kermani TA, Aydin SZ, Cronholm PF, Davis T, Easley E, Gul A, Mahr A, McAlear CA, Milman N, Robson JC, Tomasson G, Direskeneli H, Merkel PA (2017) Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016. J Rheumatol. https://doi.org/10.3899/jrheum.161467
Michel BA, Arend WP, Hunder GG (1996) Clinical differentiation between giant cell (temporal) arteritis and Takayasu’s arteritis. J Rheumatol 23(1):106–111
Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ (2015) Extra-cranial giant cell arteritis and Takayasu arteritis: how similar are they? Semin Arthritis Rheum 44(6):724–728
Stone JR, Bruneval P, Angelini A, Bartoloni G, Basso C, Batoroeva L, Buja LM, Butany J, d’Amati G, Fallon JT, Gittenberger-de Groot AC, Gouveia RH, Halushka MK, Kelly KL, Kholova I, Leone O, Litovsky SH, Maleszewski JJ, Miller DV, Mitchell RN, Preston SD, Pucci A, Radio SJ, Rodriguez ER, Sheppard MN, Suvarna SK, Tan CD, Thiene G, van der Wal AC, Veinot JP (2015) Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol 24(5):267–278
Hoffman GS, Calabrese LH (2014) Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 10(8):454–462
Svensson LG, Arafat A, Roselli EE, Idrees J, Clifford A, Tan C, Hoffman G, Eng C, Langford C, Rodriguez ER, Gornik HL, Blackstone E, Sabik JF 3rd, Lytle BW (2015) Inflammatory disease of the aorta: patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis. J Thorac Cardiovasc Surg 149(2 Suppl):S170–S175
Zen Y, Kasashima S, Inoue D (2012) Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease. Semin Diagn Pathol 29(4):212–218
Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM (2016) Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol 2(2):126–137
Chakravarti R, Gupta K, Swain M, Willard B, Scholtz J, Svensson LG, Roselli EE, Pettersson G, Johnston DR, Soltesz EG, Yamashita M, Stuehr D, Daly TM, Hoffman GS (2015) 14-3-3 in thoracic aortic aneurysms: identification of a novel autoantigen in large vessel vasculitis. Arthritis Rheumatol 67(7):1913–1921
Kistner A, Bigler MB, Glatz K, Egli SB, Baldin FS, Marquardsen FA, Mehling M, Rentsch KM, Staub D, Aschwanden M, Recher M, Daikeler T, Berger CT (2017) Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kew469
Nesher G (2014) Autoimmune aspects of giant cell arteritis. Isr Med Assoc J 16(7):454–455
Kuret T, Lakota K, Hocevar A, Burja B, Cucnik S, Sodin-Semrl S (2018) Evaluating the utility of autoantibodies for disease activity and relapse in giant cell arteritis. J Biol Regul Homeost Agents 32(2):313–319
Espinosa G, Tassies D, Font J, Munoz-Rodriguez FJ, Cervera R, Ordinas A, Reverter JC, Ingelmo M (2001) Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 31(1):12–20
Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, Martin J, Kotter I, Henes JC, Melchers I, Vaith P, Schmidt RE, Witte T (2012) Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 71(6):943–947
Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L (2011) Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 53(1):174–180
van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, Roffel MP, Roozendaal C, Kluin PM, Bos NA, Boots AM, Brouwer E (2014) Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 66(7):1927–1938
Clement M, Galy A, Bruneval P, Morvan M, Hyafil F, Benali K, Pasi N, Deschamps L, Pellenc Q, Papo T, Nicoletti A, Sacre K (2016) Tertiary lymphoid organs in Takayasu arteritis. Front Immunol 7:158
Ladich E, Yahagi K, Romero ME, Virmani R (2016) Vascular diseases: aortitis, aortic aneurysms, and vascular calcification. Cardiovasc Pathol 25(5):432–441
Ly KH, Regent A, Tamby MC, Mouthon L (2010) Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev 9(10):635–645
Weyand CM, Liao YJ, Goronzy JJ (2012) The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol 32(3):259–265
Schaufelberger C, Andersson R, Nordborg E, Hansson GK, Nordborg C, Wahlstrom J (2008) An uneven expression of T cell receptor V genes in the arterial wall and peripheral blood in giant cell arteritis. Inflammation 31(6):372–383
Fais S, Burgio VL, Silvestri M, Capobianchi MR, Pacchiarotti A, Pallone F (1994) Multinucleated giant cells generation induced by interferon-gamma. Changes in the expression and distribution of the intercellular adhesion molecule-1 during macrophages fusion and multinucleated giant cell formation. Lab Investig 71(5):737–744
Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349(2):160–169
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260(5107):547–549
Weyand CM, Goronzy JJ (2013) Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9(12):731–740
Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121(7):906–915
Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, Warrington KJ (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356
Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, Warrington KJ (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54(3):463–470
Corbera-Bellalta M, Planas-Rigol E, Lozano E, Terrades-Garcia N, Alba MA, Prieto-Gonzalez S, Garcia-Martinez A, Albero R, Enjuanes A, Espigol-Frigole G, Hernandez-Rodriguez J, Roux-Lombard P, Ferlin WG, Dayer JM, Kosco-Vilbois MH, Cid MC (2016) Blocking interferon gamma reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 75(6):1177–1186
Shirai T, Hilhorst M, Harrison DG, Goronzy JJ, Weyand CM (2015) Macrophages in vascular inflammation--from atherosclerosis to vasculitis. Autoimmunity 48(3):139–151
Salvarani C, Casali B, Nicoli D, Farnetti E, Macchioni P, Catanoso MG, Chen Q, Bajocchi G, Boiardi L (2003) Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 48(11):3219–3223
Enjuanes A, Benavente Y, Hernandez-Rodriguez J, Queralt C, Yague J, Jares P, de Sanjose S, Campo E, Cid MC (2012) Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology (Oxford) 51(5):841–851
Gonzalez-Gay MA, Oliver J, Sanchez E, Garcia-Porrua C, Paco L, Lopez-Nevot MA, Ollier WE, Martin J (2005) Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 32(11):2178–2182
Borkowski A, Younge BR, Szweda L, Mock B, Bjornsson J, Moeller K, Goronzy JJ, Weyand CM (2002) Reactive nitrogen intermediates in giant cell arteritis: selective nitration of neocapillaries. Am J Pathol 161(1):115–123
Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, Ciudad M, Leguy V, Berthier S, Vinit J, Manckoundia P, Maillefert JF, Besancenot JF, Aho-Glele S, Olsson NO, Lorcerie B, Guillevin L, Mouthon L, Saas P, Bateman A, Martin L, Janikashvili N, Larmonier N, Bonnotte B (2012) Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 64(11):3788–3798
Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ (2000) Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43(5):1041–1048
Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T (2019) Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis 78(7):1012–1014
Gloor AD, Yerly D, Adler S, Reichenbach S, Kuchen S, Seitz M, Villiger PM (2018) Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology (Oxford) 57(10):1795–1801
Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, Fouret P, Musset L, Benveniste O, Six A, Klatzmann D, Saadoun D, Cacoub P (2012) Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 64(6):2001–2011
Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, Dolzani P, Versari A, Casali M, Magnani L, Pignotti E, Pipitone N, Croci S, Meliconi R, Salvarani C (2017) Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol 35 Suppl 103(1):102–110
Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, Ji Z, Ma L, Zhang Z, Zhang Z, Zhao Z, Hou J, Dai S, Yang C, Jiang L (2016) The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol 34(3 Suppl 97):S21–S27
Chauhan SK, Tripathy NK, Sinha N, Nityanand S (2006) T-cell receptor repertoire of circulating gamma delta T-cells in Takayasu’s arteritis. Clin Immunol 118(2-3):243–249
Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P (2015) Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 67(5):1353–1360
Chapelon-Abric C, Saadoun D, Marie I, Comarmond C, Desbois AC, Domont F, Savey L, Cacoub P (2017) Sarcoidosis with Takayasu arteritis: a model of overlapping granulomatosis A report of seven cases and literature review. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.13137
Gravanis MB (2000) Giant cell arteritis and Takayasu aortitis: morphologic, pathogenetic and etiologic factors. Int J Cardiol 75(Suppl 1):S21–S33 discussion S5-6
Goel R, Kabeerdoss J, Ram B, Prakash JA, Babji S, Nair A, Jeyaseelan L, Jeyaseelan V, Mathew J, Balaji V, Joseph G, Danda D (2017) Serum cytokine profile in Asian Indian patients with Takayasu arteritis and its association with disease activity. Open Rheumatol J 11:23–29
Tripathy NK, Chauhan SK, Nityanand S (2004) Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu’s arteritis. Clin Exp Immunol 138(2):369–374
Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey L, Domont F, Cacoub P, Saadoun D (2016) Biotherapies in large vessel vasculitis. Autoimmun Rev 15(6):544–551
Bienvenu B, Ly KH, Lambert M, Agard C, Andre M, Benhamou Y, Bonnotte B, de Boysson H, Espitia O, Fau G, Fauchais AL, Galateau-Salle F, Haroche J, Heron E, Lapebie FX, Liozon E, Luong Nguyen LB, Magnant J, Manrique A, Matt M, de Menthon M, Mouthon L, Puechal X, Pugnet G, Quemeneur T, Regent A, Saadoun D, Samson M, Sene D, Smets P, Yelnik C, Sailler L, Mahr A, Groupe d’Etude Francais des Arterites des gros Vaisseaux utAotFdMA-IeA-IR (2016) Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Int 37(3):154–165
Matteson EL, Buttgereit F, Dejaco C, Dasgupta B (2016) Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin N Am 42(1):75–90, viii
Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49
Restuccia G, Boiardi L, Cavazza A, Catanoso M, Macchioni P, Muratore F, Cimino L, Aldigeri R, Crescentini F, Pipitone N, Salvarani C (2016) Flares in biopsy-proven giant cell arteritis in Northern Italy: characteristics and predictors in a long-term follow-up study. Medicine. 95(19):e3524
Nakagomi D, Jayne D (2016) Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 55(7):1159–1171
Aydin SZ, Merkel PA, Direskeneli H (2015) Outcome measures for Takayasu’s arteritis. Curr Opin Rheumatol 27(1):32–37
Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart R, Whitlock M, Schmidt WA (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636–643
Loricera J, Blanco R, Hernandez JL, Carril JM, Martinez-Rodriguez I, Canga A, Peiro E, Alonso-Gutierrez J, Calvo-Rio V, Ortiz-Sanjuan F, Mata C, Pina T, Gonzalez-Vela MC, Martinez-Amador N, Gonzalez-Gay MA (2015) Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 33(2 Suppl 89):S-19-31
Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G, Itaka Study G (2005) Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 53(1):100–107
Marie I, Proux A, Duhaut P, Primard E, Lahaxe L, Girszyn N, Louvel JP, Levesque H (2009) Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine 88(3):182–192
Houthuizen P, Polak PE, Edelbroek MA, Peels CH (2009) Giant cell arteritis as a cardiovascular entity. Neth Heart J 17(7-8):281–283
Nuenninghoff DM, Matteson EL (2003) The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 21(6 Suppl 32):S29–S34
Schmidt WA (2013) Imaging in vasculitis. Best Pract Res Clin Rheumatol 27(1):107–118
Germano G, Monti S, Ponte C, Possemato N, Caporali R, Salvarani C, Macchioni P, Pipitone N (2017) The role of ultrasound in the diagnosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol 103:194–198
Berger CT, Sommer G, Aschwanden M, Staub D, Rottenburger C, Daikeler T (2018) The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. Swiss Med Wkly 148:w14661
Jiemy WF, Heeringa P, Kamps J, van der Laken CJ, Slart R, Brouwer E (2018) Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: current status and future prospects. Autoimmun Rev 17(7):715–726
Brkic A, Terslev L, Moller Dohn U, Torp-Pedersen S, Schmidt WA, Diamantopoulos AP (2019) Clinical applicability of ultrasound in systemic large vessel vasculitides. Arthritis Rheumatol. https://doi.org/10.1002/art.41039
Blockmans D (2012) Diagnosis and extension of giant cell arteritis. Contribution of imaging techniques. Presse Med 41(10):948–954
Pletcher MJ, Pignone M (2011) Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation 123(10):1116–1124
Suzuki T, Bossone E, Sawaki D, Janosi RA, Erbel R, Eagle K, Nagai R (2013) Biomarkers of aortic diseases. Am Heart J 165(1):15–25
Monach PA (2014) Biomarkers in vasculitis. Curr Opin Rheumatol 26(1):24–30
Olthof SC, Krumm P, Henes J, Nikolaou K, la Fougere C, Pfannenberg C, Schwenzer N (2018) Imaging giant cell arteritis and aortitis in contrast enhanced 18F-FDG PET/CT: which imaging score correlates best with laboratory inflammation markers? Eur J Radiol 99:94–102
Salvarani C, Cantini F, Boiardi L, Hunder GG (2003) Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 21(6 Suppl 32):S23–S28
Hoffman GS, Ahmed AE (1998) Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 66(Suppl 1):S191–S194 discussion S5
O’Connor TE, Carpenter HE, Bidari S, Waters MF, Hedna VS (2014) Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurol 14:62
Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120(11):919–929
O'Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, Veale DJ, Murphy CC, Fearon U, Molloy E (2015) Regulation of inflammation and angiogenesis in giant cell arteritis by acute-phase serum amyloid A. Arthritis Rheumatol 67(9):2447–2456
Hachulla E, Saile R, Parra HJ, Hatron PY, Gosset D, Fruchart JC, Devulder B (1991) Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol 9(2):157–163
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97–111
Liu M, Liu X, Ren P, Li J, Chai Y, Zheng SJ, Chen Y, Duan ZP, Li N, Zhang JY (2014) A cancer-related protein 14-3-3zeta is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma. Tumour Biol 35(5):4247–4256
Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewe R, van der Heijde D, Murphy M, Marotta A (2015) 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol 42(9):1587–1594
Funami K, Matsumoto M, Obuse C, Seya T (2016) 14-3-3-zeta participates in TLR3-mediated TICAM-1 signal-platform formation. Mol Immunol 73:60–68
Schuster TB, Costina V, Findeisen P, Neumaier M, Ahmad-Nejad P (2011) Identification and functional characterization of 14-3-3 in TLR2 signaling. J Proteome Res 10(10):4661–4670
Rodriguez-Pla A, Martinez-Murillo F, Savino PJ, Eagle RC Jr, Seo P, Soloski MJ (2009) MMP-12, a novel matrix metalloproteinase associated with giant cell arteritis. Rheumatology (Oxford) 48(11):1460–1461
O’Connell D, Bouazza B, Kokalari B, Amrani Y, Khatib A, Ganther JD, Tliba O (2015) IFN-gamma-induced JAK/STAT, but not NF-kappaB, signaling pathway is insensitive to glucocorticoid in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 309(4):L348–L359
Serra R, Butrico L, Fugetto F, Chibireva MD, Malva A, De Caridi G, Massara M, Barbetta A, Cannistra M, de Franciscis S (2016) Updates in pathophysiology, diagnosis and management of Takayasu arteritis. Ann Vasc Surg 35:210–225
Pointer CB, Wenzel TJ, Klegeris A (2019) Extracellular cardiolipin regulates select immune functions of microglia and microglia-like cells. Brain Res Bull 146:153–163
Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford) 45(5):545–548
Tamura N, Maejima Y, Tezuka D, Takamura C, Yoshikawa S, Ashikaga T, Hirao K, Isobe M (2017) Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 70(3):278–285
Alibaz-Oner F, Yentur SP, Saruhan-Direskeneli G, Direskeneli H (2015) Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clin Exp Rheumatol 33(2 Suppl 89):S-32-5
van der Geest KS, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S, Roffel MP, Boots AM, Brouwer E (2015) Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford) 54(8):1397–1402
Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36(9):1286–1294
Dasgupta B, Panayi GS (1990) Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 29(6):456–458
Marquez A, Hernandez-Rodriguez J, Cid MC, Solans R, Castaneda S, Fernandez-Contreras ME, Ramentol M, Morado IC, Narvaez J, Gomez-Vaquero C, Martinez-Taboada VM, Ortego-Centeno N, Sopena B, Monfort J, Garcia-Villanueva MJ, Caminal-Montero L, de Miguel E, Blanco R, Spanish GCAC, Palm O, Molberg O, Latus J, Braun N, Moosig F, Witte T, Beretta L, Santaniello A, Pazzola G, Boiardi L, Salvarani C, Gonzalez-Gay MA, Martin J (2014) Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis 73(9):1742–1745
Carmona FD, Coit P, Saruhan-Direskeneli G, Hernandez-Rodriguez J, Cid MC, Solans R, Castaneda S, Vaglio A, Direskeneli H, Merkel PA, Boiardi L, Salvarani C, Gonzalez-Gay MA, Martin J, Sawalha AH, Spanish GCASG, Italian GCASG, Turkish Takayasu Study G, Vasculitis Clinical Research C (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953
Palomino-Morales RJ, Vazquez-Rodriguez TR, Torres O, Morado IC, Castaneda S, Miranda-Filloy JA, Callejas-Rubio JL, Fernandez-Gutierrez B, Gonzalez-Gay MA, Martin J (2010) Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Res Ther 12(2):R51
Ahn JK, Seo JM, Yu J, Oh FS, Chung H, Yu HG (2005) Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet’s uveitis. Invest Ophthalmol Vis Sci 46(7):2458–2464
Tulunay A, Dozmorov MG, Ture-Ozdemir F, Yilmaz V, Eksioglu-Demiralp E, Alibaz-Oner F, Ozen G, Wren JD, Saruhan-Direskeneli G, Sawalha AH, Direskeneli H (2015) Activation of the JAK/STAT pathway in Behcet’s disease. Genes Immun 16(2):170–175
Torres O, Palomino-Morales R, Vazquez-Rodriguez T, Castaneda S, Morado IC, Miranda-Filloy JA, Amigo-Diaz E, Callejas-Rubio JL, Fernandez-Gutierrez B, Martin J, Gonzalez-Gay MA (2010) Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis. Clin Exp Rheumatol 28(1 Suppl 57):31–34
Dogan S, Piskin O, Solmaz D, Akar S, Gulcu A, Yuksel F, Cakir V, Sari I, Akkoc N, Onen F (2014) Markers of endothelial damage and repair in Takayasu arteritis: are they associated with disease activity? Rheumatol Int 34(8):1129–1138
Goodfellow N, Morlet J, Singh S, Sabokbar A, Hutchings A, Sharma V, Vaskova J, Masters S, Zarei A, Luqmani R (2017) Is vascular endothelial growth factor a useful biomarker in giant cell arteritis? RMD Open 3(1):e000353
Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M (2013) Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 77(2):477–483
Sun Y, Ma L, Yan F, Liu H, Ding Y, Hou J, Jiang L (2012) MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu’s arteritis. Int J Cardiol 156(2):236–238
Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, Nakamura T, Yamashita S, Matsuzawa Y (2003) Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation. 108(12):1469–1473
Liu Q, Dang A, Chen B, Lv N, Wang X, Zheng D (2014) Function of N-terminal pro-brain natriuretic peptide in Takayasu arteritis disease monitoring. J Rheumatol 41(8):1683–1688
Lozano E, Segarra M, Corbera-Bellalta M, Garcia-Martinez A, Espigol-Frigole G, Pla-Campo A, Hernandez-Rodriguez J, Cid MC (2010) Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis 69(2):434–442
Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM (2000) Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg 87(10):1391–1400
Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC (1997) Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158(5):2327–2333
Fukui S, Nunokawa T, Kobayashi S, Kamei S, Yokogawa N, Takizawa Y, Shimada K, Sugii S, Setoguchi K (2016) MMP-3 can distinguish isolated PMR from PMR with GCA: A retrospective study regarding PMR and GCA in Japan. Mod Rheumatol 26(2):259–264
Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M (2005) Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 112(2):264–269
Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M (2011) Sensitive assessment of activity of Takayasu’s arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57(16):1712–1713
Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120(8):699–708
Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi AA, Baldissera E, Sabbadini MG (2011) Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 155(7):425–433
Iwagaitsu S, Naniwa T (2017) Improvement of arterial wall lesions in parallel with decrease of plasma pentraxin-3 levels in a patient with refractory Takayasu arteritis after treatment with tocilizumab. Case Rep Rheumatol 2017:4580967
Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B, Bozzolo EP, Greco M, Rovere-Querini P, Baldissera E, Del Maschio A, Mantovani A, De Cobelli F, Sabbadini MG, Manfredi AA (2014) Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther 16(6):479
Alibaz-Oner F, Aksu K, Yentur SP, Keser G, Saruhan-Direskeneli G, Direskeneli H (2016) Plasma pentraxin-3 levels in patients with Takayasu’s arteritis during routine follow-up. Clin Exp Rheumatol 34(3 Suppl 97):S73–S76
Mahadavan G, Nguyen TH, Horowitz JD (2014) Brain natriuretic peptide: a biomarker for all cardiac disease? Curr Opin Cardiol 29(2):160–166
Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Segarra M, Espigol-Frigole G, Prieto-Gonzalez S, Hernandez-Rodriguez J, Preciado S, Lavilla R, Cid MC (2017) Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis 76(9):1624–1634
Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, Luqmani RA, Neogi T, Seo P, Suppiah R, Tomasson G, Merkel PA (2011) Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 38(7):1471–1479
Nakagomi D, Cousins C, Sznajd J, Furuta S, Mohammad AJ, Luqmani R, Jayne D (2017) Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS). Clin Exp Rheumatol 35 Suppl 103(1):139–145
Grosse K, Witte T, Moosig F, Hoyer BF, Lansche C, Schmidt RE, Baerlecken NT (2014) Association of ferritin antibodies with Takayasu arteritis. Clin Rheumatol 33(10):1523–1526
Regent A, Dib H, Ly KH, Agard C, Tamby MC, Tamas N, Weksler B, Federici C, Broussard C, Guillevin L, Mouthon L (2011) Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther 13(3):R107
Lopez-Hoyos M, Alvarez L, Ruiz Soto M, Blanco R, Jose Bartolome M, Martinez-Taboada VM (2008) Serum levels of antibodies to Chlamydia pneumoniae and human HSP60 in giant cell arteritis patients. Clin Exp Rheumatol 26(6):1107–1110
Weyand CM, Goronzy JJ (1995) Giant cell arteritis as an antigen-driven disease. Rheum Dis Clin N Am 21(4):1027–1039
Gilden D, White T, Khmeleva N, Katz BJ, Nagel MA (2016) Blinded search for varicella zoster virus in giant cell arteritis (GCA)-positive and GCA-negative temporal arteries. J Neurol Sci 364:141–143
Gillot JM, Masy E, Davril M, Hachulla E, Hatron PY, Devulder B, Dessaint JP (1997) Elastase derived elastin peptides: putative autoimmune targets in giant cell arteritis. J Rheumatol 24(4):677–682
Dovrat S, Caspi M, Zilberberg A, Lahav L, Firsow A, Gur H, Rosin-Arbesfeld R (2014) 14-3-3 and beta-catenin are secreted on extracellular vesicles to activate the oncogenic Wnt pathway. Mol Oncol 8(5):894–911
Fleming SD, Tsokos GC (2006) Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev 5(2):89–92
Nowling TK, Gilkeson GS (2011) Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 13(6):250
Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA (2010) Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc Natl Acad Sci U S A 107(26):11993–11998
Caja S, Maki M, Kaukinen K, Lindfors K (2011) Antibodies in celiac disease: implications beyond diagnostics. Cell Mol Immunol 8(2):103–109
Elkon K, Casali P (2008) Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 4(9):491–498
Graver JC, Boots AMH, Haacke EA, Diepstra A, Brouwer E, Sandovici M (2019) Massive B-Cell infiltration and organization into artery tertiary lymphoid organs in the aorta of large vessel giant cell arteritis. Front Immunol 10:83
Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71(1):75–79
McGowan JE, Kratch J, Chattopadhyay S, Joe B, Conti HR, Chakravarti R (2017) Bioinformatic analysis reveals new determinants of antigenic 14-3-3 proteins and a novel antifungal strategy. PLoS One 12(12):e0189503
Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV (2010) Serum ferritin: past, present and future. Biochim Biophys Acta 1800(8):760–769
Pagnoux C, Cohen P, Guillevin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24(2 Suppl 41):S71–S81 Epub 2006/07/25
Helweg-Larsen J, Tarp B, Obel N, Baslund B (2002) No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford) 41(4):445–449
Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, Grose C, Carpenter JE, Rempel A, Bos N, Kandasamy B, Lear-Kaul K, Holmes DB, Bennett JL, Cohrs RJ, Mahalingam R, Mandava N, Eberhart CG, Bockelman B, Poppiti RJ, Tamhankar MA, Fogt F, Amato M, Wood E, Durairaj V, Rasmussen S, Petursdottir V, Pollak L, Mendlovic S, Chatelain D, Keyvani K, Brueck W, Nagel MA (2015) Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 84(19):1948–1955
Muratore F, Croci S, Tamagnini I, Zerbini A, Bellafiore S, Belloni L, Boiardi L, Bisagni A, Pipitone N, Parmeggiani M, Cavazza A, Salvarani C (2017) No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Semin Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2017.02.005
Russo MG, Waxman J, Abdoh AA, Serebro LH (1995) Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism? Arthritis Rheum 38(3):374–380
Manna R, Latteri M, Cristiano G, Todaro L, Scuderi F, Gasbarrini G (1998) Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol 37(2):208–210
Arora P, Malik M, Sachdeva R, Saxena L, Das J, Ramachandran VG, Pal R (2017) Innate and humoral recognition of the products of cell death: differential antigenicity and immunogenicity in lupus. Clin Exp Immunol 187(3):353–368
Kaplan A, Bueno M, Fournier AE (2017) Extracellular functions of 14-3-3 adaptor proteins. Cell Signal 31:26–30
McGowan J, Peter C, Chattopadhyay S, Chakravarti R (2019) 14-3-3zeta: a novel immunogen promotes inflammatory cytokine production. Front Immunol. https://doi.org/10.3389/fimmu.2019.01553
Ma J, Luo X, Wu Q, Chen Z, Kou L, Wang H (2010) Circulation levels of acute phase proteins in patients with Takayasu arteritis. J Vasc Surg. 201051 (3):700-6. Epub 2010/01/27. PubMed PMID: 20100644 https://doi.org/10.1016/j.jvs.2009.09.038
Funding
We thank the American Heart Association (15SDG2308025) and UT startup funds for their financial support to Dr. Ritu Chakravarti.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Benhuri, B., ELJack, A., Kahaleh, B. et al. Mechanism and biomarkers in aortitis––a review. J Mol Med 98, 11–23 (2020). https://doi.org/10.1007/s00109-019-01838-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-019-01838-1